Is today’s IVF built for today’s demand? Current IVF practices were built for a different era. Fertilis is an Australian medtech company redesigning IVF, developing precision tools that fit seamlessly into existing labs and simplify the most technically demanding IVF procedures, helping embryologists work faster, more consistently, and with greater control. Fertilis believes the answer isn’t replacing embryologists, it’s redesigning procedures to let them do more. Founded by globally recognised IVF leaders Prof. Jeremy Thompson and Prof. David Gardner, our mission is simple: protect the embryo while amplifying the embryologist. We develop single-use, micro-fabricated consumables that integrate seamlessly into existing labs, delivering better consistency, higher efficiency, and a clearer path to scale. Our embryo-centric tools simplify the most delicate and technically demanding steps in IVF: 1. Our first product, microICSI, is the first true step-change for fertilisation in more than 35 years. It reduces stress on eggs, shortens procedure time, and makes the technique easier for both experienced and junior embryologists. microICSI is currently in human clinical trials in Japan and Australia, with encouraging early safety and efficacy data. FDA and EU-MDR approvals are expected in the coming months. 2. Our second product, microBiopsy, is the only purpose-designed tool for embryo biopsy and genetic testing. This is advancing rapidly through pre-clinical testing and has already received strong interest from leading Japanese clinics. We are proud to be exhibiting at WHX Osaka and look forward to meeting Japanese IVF leaders and potential partners.